

Programs	Indication	Market Size	Status
Clinical <i>d</i>-OSAB™	Acute Ischemic Stroke	Ischemic stroke strikes more than 880,000 persons in the US; 880,000 persons in the EU; and 1,400,000 persons in India annually. The total annual US, EU and India market size for <i>d</i> -OSAB as a stroke therapy is estimated at \$18.5 billion dollars.	Phase IIa ¹
<i>d</i>-OSAB™	Chronic Heart Failure	Chronic Heart Failure (CHF) affects more than 5,000,000 people and is associated with more than 400,000 deaths each year in North America. Over 6,500,000 people in the EU are affected each year. The total annual US and EU market for <i>d</i> -OSAB as a Chronic Heart Failure therapy is estimated at \$61.7 billion dollars.	Phase II planned
1. This Phase II trial is a single-site, non-regulatory study performed to establish safety and efficacy of the therapeutic			

Programs	Indication	Market Size	Status
<u>Fluid Sterilization</u> PathPure™	Prion-free bovine sera	Bovine sera are used throughout the biopharmaceutical industry to develop drugs and vaccines. Sera are at risk for contamination and transmission of infectious pathogens including viruses and prions. The US bovine sera market is valued at approximately \$1.7 billion dollars.	Animal validation studies
PathPure™	Human-derived blood products	Many human derived-blood products including red blood cells, platelets, fresh frozen plasma and protein concentrates are at risk for infectious pathogen contamination. Application of the PathPure Platform to render these these products pathogen-free is presently being investigated.	Pre-clinical studies